Indian drugmaker Biocon has announced the signing of an out-licensing agreement with Ajanta Pharma to market its vertically ...

Ajanta Pharma shares gained 3% despite a weak market as analysts turned bullish on its Biocon partnership, semaglutide ...

Biocon Biologics, a fully integrated global biosimilars company and subsidiary of India’s Biocon Ltd, announced that it has ...

Ajanta Pharma share price rose as it has entered into an in-licensing agreement with Biocon Limited for the right to market ...

Four pharma stocks to watch today as Lupin signs a peptide API deal, Dr Reddy’s and Aurobindo face FDA observations, and Biocon clears a global launch.

Given Ajanta’s improving business mix and robust cash generation, its share valuation appears reasonable for a company ...

Ajanta Pharma plans to sell generic semaglutide in 26 countries, in a partnership with Biocon, capitalizing on patent ...

Biocon’s subsidiary Biocon Pharma has received the Food and Drug Administration’s permission for norepinephrine bitartrate injection (4 mg/4 ml, 1 mg/ml) in a single-dose vial, the company said in a ...

Yogesh Agrawal, MD of Ajanta Pharma outlined Ajanta Pharma’s strategy to capitalise on the opportunity through its ...

Roche ($RHHBY) could have Indian competition for Herceptin sooner than it thought. Now that the Swiss drugmaker has decided to forego a patent fight over the breast ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...